The day encompassed a plethora of presentations on TBI, with the speakers approaching subjects such as disorders of consciousness, the role of Brain-Derived Neurotrophic Factor (BDNF), diffuse axonal injury, the impact of TBI on the Alzheimer's Disease, personalized approaches to TBI management, traumatic brain hemorrhage, the role of oxiracetam nanodelivery for the enhancement of memory, the complications of decompressive craniotomies following TBI, neurovascular therapies and the innovative PRESENT (Patient REgistry – Short Essential NeuroTrauma). The gene discussed is BDNF; the disease is early-onset autosomal dominant Alzheimer disease.